This activity is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals globally, excluding the UK.
Join expert Ralph Audehm, MD, for a practical, case-based exploration of long-term, patient-centric monitoring strategies in primary care obesity management. This session examines how to navigate anti-obesity medication adherence, manage gastrointestinal side effects and blood pressure changes, adjust concomitant weight-promoting medications, and implement structured shared decision-making pathways to sustain long-term treatment outcomes.
Session Highlights
- Establish long-term adherence plans from medication initiation, recognizing obesity as a chronic condition that requires continuous management and proactive counseling on weight rebound risks.
- Apply phase-specific strategies to prevent and manage gastrointestinal side effects during GLP-1-based therapy escalation, utilizing dietary adjustments, hydration, and tailored dose titration.
- Evaluate lightheadedness or low blood pressure during therapy as potential triggers to reassess hydration status, blood glucose, and concomitant antihypertensive or antidiabetic treatments.
- Review concomitant patient medications to identify weight-promoting agents and transition to non-weight-promoting therapeutic alternatives where appropriate.
This is Module Four of Four, See Modules One, Two and Three Here.
Prefer to read? see our Key Clinical Summary Here
Who Should Watch
This activity is intended for primary care providers, nurse practitioners, physician assistants/associates, pharmacists, and other healthcare providers who care for patients with obesity.
Faculty
Dr Ralph Audehm is a general practitioner who graduated from Melbourne University in 1984 and has worked for over 25 years in general practice. He is experienced in managing all types of patients. He obtained a Diploma from the Royal Australian College of Obstetricians and Gynaecologists in 1987 and is an Honorary Clinical Associate Professor at the Department of General Practice, University of Melbourne. He has had a long-standing interest in the management of chronic conditions in General Practice especially diabetes and heart disease.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr Ralph Audehm, faculty for this educational activity, has the following relevant financial relationships: Advisory Board and Consultant for AstraZeneca, Boehringer Ingelheim, Lilly and NovoNordisk.
The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Associate Continuing Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.
Pharmacy Continuing Education
Partners designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-26-295-H01-P
Type of Activity: Knowledge
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information
There is no fee for this educational activity.
This continuing education activity is active starting September 10th 2026, and will expire on August 4th 2027.
Estimated time to complete this activity: 15 Minutes